Indoco Remedies Ltd (INDOCO) is currently trading at 214.75 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Indoco Remedies is an Indian pharmaceutical company manufacturing and marketing branded formulations, regulated-market generics, APIs, contract-manufactured products and research services through a multi-facility manufacturing and development network. Indoco Remedies crossed Rs. 500 crore in quarterly consolidated revenue for the first time, reaching Rs. 506.9 crore in Q2 FY27, although standalone revenue grew only 2% because domestic formulations declined. International formulations were the principal growth engine, increasing 12.1%, with regulated markets up 21.1%, Europe up 23.5% and the United States up 16.4% during the quarter. Domestic portfolio concentration remains a key weakness: Cyclopam, Cital and dental products grew strongly, but seasonal acute brands including Febrex Plus, Oxipod and ATL declined materially. Operating improvement remains vulnerable to external costs, with approximately Rs. 13 crore of additional freight expense and roughly 30% higher material, handling and related costs affecting margins.

Over the past 52 weeks, Indoco Remedies Ltd has traded between a low of ₹163.70 and a high of ₹287.35. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Indoco Remedies Ltd has a market capitalization of approximately 1,992.69. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Indoco Remedies Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 62.70 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,992.69 Cr, Indoco Remedies Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Indoco Remedies Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Indoco Remedies Ltd is 62.70. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Indoco Remedies reported consolidated revenue of ₹506.9 crore in Q2 FY27, up 7.4% year-on-year from ₹471.8 crore.

Indoco Remedies’ board is scheduled to consider and approve the unaudited Q2 FY2026-27 results on October 27, 2026.

Indoco said the USFDA completed a routine inspection of its Patalganga, Navi Mumbai API facility in September 2025 with zero Form 483 observations.

Consolidated profit attributable to equity shareholders was reported at ₹64.99 crore in Q1 FY27, compared with a loss of ₹35.79 crore in Q1 FY26.